Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
803 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Parkinson's Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H1 2017, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape. Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson's disease. Parkinson's disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 32, 41, 5, 180, 48 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 1, 46, 14 and 1 molecules, respectively. Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 8 Parkinson's Disease - Overview 9 Parkinson's Disease - Therapeutics Development 10 Parkinson's Disease - Therapeutics Assessment 50 Parkinson's Disease - Companies Involved in Therapeutics Development 70 Parkinson's Disease - Drug Profiles 154 Parkinson's Disease - Dormant Projects 737 Parkinson's Disease - Discontinued Products 751 Parkinson's Disease - Product Development Milestones 753 Appendix 765
List of Tables
Number of Products under Development for Parkinson's Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 Products under Development by Companies, H1 2017 (Contd..14), H1 2017 Products under Development by Companies, H1 2017 (Contd..15), H1 2017 Products under Development by Companies, H1 2017 (Contd..16), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H1 2017 Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H1 2017 Parkinson's Disease - Pipeline by AbbVie Inc, H1 2017 Parkinson's Disease - Pipeline by AC Immune SA, H1 2017 Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H1 2017 Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H1 2017 Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2017 Parkinson's Disease - Pipeline by Amabiotics SAS, H1 2017 Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H1 2017 Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H1 2017 Parkinson's Disease - Pipeline by Angita BV, H1 2017 Parkinson's Disease - Pipeline by Antoxis Ltd, H1 2017 Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017 Parkinson's Disease - Pipeline by APeT Holding BV, H1 2017 Parkinson's Disease - Pipeline by ApoPharma Inc, H1 2017 Parkinson's Disease - Pipeline by Aposense Ltd, H1 2017 Parkinson's Disease - Pipeline by Araclon Biotech SL, H1 2017 Parkinson's Disease - Pipeline by ArmaGen Inc, H1 2017 Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H1 2017 Parkinson's Disease - Pipeline by Asceneuron SA, H1 2017 Parkinson's Disease - Pipeline by AstraZeneca Plc, H1 2017 Parkinson's Disease - Pipeline by Berg LLC, H1 2017 Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H1 2017 Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H1 2017 Parkinson's Disease - Pipeline by BioArctic AB, H1 2017 Parkinson's Disease - Pipeline by Biogen Inc, H1 2017 Parkinson's Disease - Pipeline by BioHealthonomics Inc, H1 2017 Parkinson's Disease - Pipeline by Biopharm GmbH, H1 2017 Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Cardax Inc, H1 2017 Parkinson's Disease - Pipeline by Carna Biosciences Inc, H1 2017 Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H1 2017 Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H1 2017 Parkinson's Disease - Pipeline by Clera Inc, H1 2017 Parkinson's Disease - Pipeline by Clevexel Pharma SAS, H1 2017 Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Corium International Inc, H1 2017 Parkinson's Disease - Pipeline by Curemark LLC, H1 2017 Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Easywell Biomedical Inc , H1 2017 Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Eli Lilly and Company, H1 2017 Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H1 2017 Parkinson's Disease - Pipeline by Evotec AG, H1 2017 Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Forma Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by FPRT Bio Inc, H1 2017 Parkinson's Disease - Pipeline by Genecode AS, H1 2017 Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017 Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017 Parkinson's Disease - Pipeline by GenKyoTex SA, H1 2017 Parkinson's Disease - Pipeline by Genmab A/S, H1 2017 Parkinson's Disease - Pipeline by Genzyme Corp, H1 2017 Parkinson's Disease - Pipeline by H. Lundbeck A/S, H1 2017 Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H1 2017 Parkinson's Disease - Pipeline by Herantis Pharma Plc, H1 2017 Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017 Parkinson's Disease - Pipeline by HitGen LTD, H1 2017 Parkinson's Disease - Pipeline by Huons Co Ltd, H1 2017 Parkinson's Disease - Pipeline by ICB International Inc, H1 2017 Parkinson's Disease - Pipeline by Immungenetics AG, H1 2017 Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H1 2017 Parkinson's Disease - Pipeline by InnoMedica Holding AG, H1 2017 Parkinson's Disease - Pipeline by Intec Pharma ltd, H1 2017 Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H1 2017 Parkinson's Disease - Pipeline by International Stem Cell Corp, H1 2017 Parkinson's Disease - Pipeline by Io Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Kainos Medicine Inc, H1 2017 Parkinson's Disease - Pipeline by Khondrion BV, H1 2017 Parkinson's Disease - Pipeline by KineMed Inc, H1 2017 Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H1 2017 Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H1 2017 Parkinson's Disease - Pipeline by Longevity Biotech Inc, H1 2017 Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H1 2017 Parkinson's Disease - Pipeline by M et P Pharma AG, H1 2017 Parkinson's Disease - Pipeline by M's Science Corp, H1 2017 Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H1 2017 Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H1 2017 Parkinson's Disease - Pipeline by MedImmune LLC, H1 2017 Parkinson's Disease - Pipeline by Merck & Co Inc, H1 2017 Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2017 Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H1 2017 Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H1 2017 Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Montisera Ltd, H1 2017 Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H1 2017 Parkinson's Disease - Pipeline by Neonc Technologies Inc, H1 2017 Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H1 2017 Parkinson's Disease - Pipeline by Neuralstem Inc, H1 2017 Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017 Parkinson's Disease - Pipeline by NeuroDerm Ltd, H1 2017 Parkinson's Disease - Pipeline by NeuroNascent Inc, H1 2017 Parkinson's Disease - Pipeline by NeurOp Inc, H1 2017 Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H1 2017 Parkinson's Disease - Pipeline by New World Laboratories Inc, H1 2017 Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H1 2017 Parkinson's Disease - Pipeline by nLife Therapeutics SL, H1 2017 Parkinson's Disease - Pipeline by Novartis AG, H1 2017 Parkinson's Disease - Pipeline by Novo Nordisk A/S, H1 2017 Parkinson's Disease - Pipeline by NsGene A/S (Inactive), H1 2017 Parkinson's Disease - Pipeline by Omeros Corp, H1 2017 Parkinson's Disease - Pipeline by Oncodesign SA, H1 2017 Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Parkinson's Disease - Pipeline by OPKO Health Inc, H1 2017 Parkinson's Disease - Pipeline by Origenis GmbH, H1 2017 Parkinson's Disease - Pipeline by Orion Oyj, H1 2017 Parkinson's Disease - Pipeline by Oryzon Genomics SA, H1 2017 Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H1 2017 Parkinson's Disease - Pipeline by ParkCell AB, H1 2017 Parkinson's Disease - Pipeline by Parkure Ltd, H1 2017 Parkinson's Disease - Pipeline by Peptron Inc, H1 2017 Parkinson's Disease - Pipeline by Pfizer Inc, H1 2017 Parkinson's Disease - Pipeline by Pharma Two B Ltd, H1 2017 Parkinson's Disease - Pipeline by Pharmaxis Ltd, H1 2017 Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Pharnext SA, H1 2017 Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H1 2017 Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H1 2017 Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H1 2017 Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Promius Pharma LLC, H1 2017 Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Prothena Corp Plc, H1 2017 Parkinson's Disease - Pipeline by reMYND NV, H1 2017 Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by SanBio Inc, H1 2017 Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Saniona AB, H1 2017 Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Shire Plc, H1 2017 Parkinson's Disease - Pipeline by Sigma-Tau SpA, H1 2017 Parkinson's Disease - Pipeline by SignPath Pharma Inc, H1 2017 Parkinson's Disease - Pipeline by Signum Biosciences Inc, H1 2017 Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017 Parkinson's Disease - Pipeline by STATegics Inc, H1 2017 Parkinson's Disease - Pipeline by Stealth BioTherapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Synthonics Inc, H1 2017 Parkinson's Disease - Pipeline by Takara Bio Inc, H1 2017 Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2017 Parkinson's Disease - Pipeline by TechnoPhage SA, H1 2017 Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H1 2017 Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H1 2017 Parkinson's Disease - Pipeline by Trevena Inc, H1 2017 Parkinson's Disease - Pipeline by UCB SA, H1 2017 Parkinson's Disease - Pipeline by UniQure NV, H1 2017 Parkinson's Disease - Pipeline by Varinel Inc, H1 2017 Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H1 2017 Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H1 2017 Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..1), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..2), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..3), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..4), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..5), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..6), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..7), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..8), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..9), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..10), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..11), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..12), H1 2017 Parkinson's Disease - Dormant Projects, H1 2017 (Contd..13), H1 2017 Parkinson's Disease - Discontinued Products, H1 2017 Parkinson's Disease - Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
